Lord, Abbett & Co’s CONMED CNMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-147,620
Closed -$11.8M 528
2024
Q1
$11.8M Sell
147,620
-238
-0.2% -$21.2K 0.04% 379
2023
Q4
$16.2M Sell
147,858
-34,205
-19% -$3.54M 0.06% 347
2023
Q3
$18.4M Sell
182,063
-3,130
-2% -$360K 0.07% 336
2023
Q2
$25.2M Sell
185,193
-145,133
-44% -$17.7M 0.09% 297
2023
Q1
$34.3M Buy
330,326
+4,117
+1% +$398K 0.12% 244
2022
Q4
$28.9M Sell
326,209
-1,415
-0.4% -$117K 0.1% 275
2022
Q3
$26.3M Buy
327,624
+1,680
+0.5% +$158K 0.1% 279
2022
Q2
$31.2M Buy
325,944
+73,872
+29% +$8.87M 0.11% 254
2022
Q1
$37.4M Buy
+252,072
New +$35.2M 0.1% 270
2018
Q3
Sell
-80,891
Closed -$5.92M 833
2018
Q2
$5.92M Sell
80,891
-157,583
-66% -$10.7M 0.02% 708
2018
Q1
$15.1M Sell
238,474
-30,756
-11% -$1.84M 0.04% 531
2017
Q4
$13.7M Sell
269,230
-1,200
-0.4% -$62.5K 0.04% 566
2017
Q3
$14.2M Hold
270,430
0.04% 548
2017
Q2
$13.8M Sell
270,430
-56,900
-17% -$2.82M 0.04% 545
2017
Q1
$14.5M Sell
327,330
-124,300
-28% -$5.35M 0.04% 505
2016
Q4
$19.9M Hold
451,630
0.06% 414
2016
Q3
$18.1M Sell
451,630
-9,600
-2% -$408K 0.06% 452
2016
Q2
$22M Buy
+461,230
New +$19.5M 0.07% 393

Other funds holding CNMD

Lord, Abbett & Co's CNMD Position: Q2 2024 in Review

Lord, Abbett & Co sold out of CONMED (CNMD) in Q2 2024, closing a stake of 147,620 shares — an estimated $11.8M sold.

Lord, Abbett & Co first reported a position in CNMD in Q2 2016 and held it in 18 quarters. The position peaked at $37.4M in Q1 2022. 290 funds tracked by Wall St. Rank hold CNMD as of Q2 2024.

  • Lord, Abbett & Co reported no remaining CONMED position as of Q2 2024 after selling out during the quarter.
  • Lord, Abbett & Co sold 147,620 CONMED shares in Q2 2024, an estimated $11.8M.
  • Lord, Abbett & Co first reported a position in CONMED in Q2 2016 and held it in 18 quarters.
  • Lord, Abbett & Co's CONMED position peaked at $37.4M in Q1 2022.
  • 290 funds tracked by Wall St. Rank held CONMED as of Q2 2024.

Based on Lord, Abbett & Co's 13F filing for Q2 2024, filed 14 Aug 2024.